ZURICH (AFP): Swiss pharmaceuticals giant Roche said Thursday (Oct 22) it is collaborating with Atea Pharmaceuticals on the development of an orally administered drug to treat coronavirus patients who have not been hospitalised.
"Roche and Atea Pharmaceuticals are joining forces in the fight against Covid-19 to develop, manufacture and distribute AT-527, Atea's investigational oral direct-acting antiviral, to people around the globe," the two companies said in a joint statement.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
